Specialties: Oncology

ClinicalInterests: Lymphoma

Education:

2006.9 - 2014.7 MD degree in Clinical Medicine, MedicalCollege of Southern Medical University, Guangzhou, China

Professionalmemberships:

Member of lymphoma Professional Committeeof Guangdong Women Doctors Association

Publications:

1            Chen F, Pang D, Guo H, Ou Q, Wu X, JiangX, Wei X, Liu S, Huang L,Liang Z, Zhou D, Li W. Clinical outcomes of newly diagnosed primary CNSlymphoma treated with ibrutinib-based combination therapy: A real-worldexperience of off-label ibrutinib use. Cancer Med. 2020;9(22):8676-8684.

2            Chen F, Pang D, Guo H, Jiang X,Liu S, Huang L, Wei X, Liang Z,Wang X, Li W. Clinicopathological Characteristics and Mutational Profiling ofAdult T-Cell Lymphoblastic Lymphoma in a Chinese Population. Cancer Manag Res.2020 ;12:3003-3012.

3            Chen F, Guo H, Mao C, Jiang X,Liu S, Huang L, Wei X, Liang Z,Zhou D, Li W. Unusual Relapse of Primary Central Nervous System Lymphoma BothInside and Outside Central Nervous System in Patient with VentriculoperitonealShunt. World Neurosurg. 2019;127:625-628.

4           Mao C^#, Chen F^#, Li Y^#, Jiang X, Liu S, GuoH, Huang L, Wei X, Liang Z, Li W^*, Tang K^*.Characteristics and Outcomes of Primary Central Nervous System Lymphoma: ARetrospective Study of 91 Cases in a Chinese Population. World Neurosurg. 2019;123:e15-e24.

5           Huang L, Zhang F, Zeng J, Guo H, LiuS, Wei X, Chen F, Jiang X,Liang Z, Liu Y, Li W. ALK expression plays different roles in anaplasticlarge-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+patients in a Chinese population. Ann Hematol. 2018;97(1):149-159.